Orinox (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Orinox, is an imidazoline‑derived nasal decongestant presented as an unknown strength/unknown form for nasal use. It relieves nasal congestion associated with the common cold, sinusitis, and allergic rhinitis in adults and children.

GNH USA supplies Orinox as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide. The company follows EU GMP standards and provides full regulatory documentation for cross‑border distribution.

Orinox, containing xylometazoline, is used to treat nasal congestion by acting on the upper‑respiratory tract. - Common cold: reduces nasal blockage and improves airflow. - Acute sinusitis: alleviates sinus pressure and congestion. - Allergic rhinitis: diminishes swelling of nasal mucosa and eases breathing.

Xylometazoline may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Burning or stinging sensation in the nose. - Nasal dryness or crusting. - Sneezing. - Mild headache. - Transient epistaxis (nosebleed).

Serious or Rare Side Effects: - Rebound nasal congestion (rhinitis medicamentosa) after prolonged use. - Elevated blood pressure. - Tachycardia or irregular heart rhythm. - Severe allergic reaction (anaphylaxis).

When using Orinox, observe the following precautions to minimize risks and ensure effectiveness. - Duration of use: limit to no more than three consecutive days to avoid rebound congestion. - Age restriction: do not use in children under 2 years of age unless directed by a physician. - Cardiovascular conditions: avoid if you have uncontrolled hypertension or heart disease without medical advice. - Nasal surgery or trauma: postpone use until healing is complete. - Pregnancy and breastfeeding: consult a healthcare professional before use. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Xylometazoline can interact with certain medicines; consider the following categories.

Major Interactions (Avoid): - Other topical nasal decongestants (e.g., oxymetazoline) – risk of excessive vasoconstriction. - Monoamine oxidase inhibitors (MAOIs) – potential for hypertensive crisis.

Moderate Interactions (Monitor Closely): - Systemic sympathomimetics (e.g., pseudoephedrine) – additive cardiovascular effects. - Antihypertensive agents (beta‑blockers, ACE inhibitors) – may reduce blood‑pressure‑lowering efficacy. - Tricyclic antidepressants – possible increase in blood pressure. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – monitor for nasal irritation.